Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL, CIN III) with Endocervical Gland Involvement
Excisional procedures—specifically LEEP, cold-knife conization, or laser conization—are the required treatment for CIN III with endocervical gland involvement, as ablative methods cannot adequately treat disease extending into the endocervical canal and are associated with higher rates of subsequent invasive cancer. 1
Why Excision is Mandatory
Ablative methods (cryotherapy, laser ablation) are contraindicated when endocervical gland involvement is present because they cannot adequately treat disease extending into the endocervical canal and carry higher rates of subsequent invasive cancer diagnosis. 1
Excisional procedures allow pathologic examination to exclude microinvasive or occult invasive carcinoma, which occurs in up to 7% of CIN 2/3 cases with unsatisfactory colposcopy. 1
Endocervical gland involvement is significantly more common in CIN III (90.9% of cases) compared to lower-grade lesions, making complete excision essential. 2
HPV 16 infection, as in this patient, is the highest-risk HPV type and warrants aggressive treatment with tissue diagnosis. 3
Excisional Treatment Options
LEEP is the preferred first-line excisional method due to its cost-effectiveness, high cure rate (>90% after single treatment), shorter operative time, and less blood loss. 1, 4, 5
LEEP provides adequate tissue for pathologic examination while maintaining excellent efficacy for lesions of any size. 5
The main limitation is that margins may be more frequently involved and harder to interpret compared to cold-knife conization. 6, 1
Cold-knife conization is the alternative excisional option with clearer margin interpretation, though it requires longer operative time and causes more bleeding. 1
- Cold-knife conization is preferred when microinvasion is suspected based on colposcopy or when LEEP margins are positive and re-excision is needed. 7, 4
Laser conization is equivalent in efficacy to other excisional methods but is less commonly used due to equipment costs. 1
Management Based on Margin Status
If Margins are Negative
Follow-up with cervical cytology at 6 months OR HPV DNA testing at 12 months is recommended. 7, 1
HPV testing at 6 months post-LEEP is highly sensitive for detecting recurrent CIN 2+, particularly for HPV 16. 1
After 2 consecutive negative results, return to routine screening, though surveillance should continue for at least 25 years given the history of CIN III. 3
If Margins are Positive
Three management options exist: (1) cervical cytology at 6 months with consideration of endocervical curettage; (2) re-excision, especially if invasion is suspected; or (3) hysterectomy if other indications exist. 7, 1
Re-excision with cold-knife conization is preferred when positive margins suggest residual high-grade disease or possible invasion. 7, 4
Endocervical curettage can be considered (category 2B evidence) to assess for residual disease in the endocervical canal. 7
Critical Pitfalls to Avoid
Never use ablative procedures (cryotherapy, laser ablation) for CIN III with endocervical involvement—this is associated with higher cancer rates and cannot adequately treat endocervical disease. 1
Do not rely on HPV testing alone for triage—immediate colposcopy or excision is required for HSIL cytology due to the 53-66% risk of CIN 2+ and 2% risk of invasive cancer. 4
Avoid hysterectomy as primary treatment unless other gynecologic indications exist (symptomatic fibroids, abnormal bleeding), as excisional procedures provide equivalent cure rates with lower morbidity. 6, 7
Do not defer treatment based on a single negative follow-up test—patients with CIN III and endocervical involvement require definitive excisional treatment before surveillance begins. 1, 4
Special Consideration for HPV 16
HPV 16 is the highest-risk type and is associated with increased persistence and recurrence risk after treatment. 3, 1
Post-treatment HPV testing specifically for HPV 16 at 6-12 months provides highly sensitive detection of recurrent disease. 1
Long-term surveillance for at least 25 years is essential given the HPV 16 infection and history of CIN III. 3